Clinical safety and efficacy of the first-in-class Rho kinase inhibitor for lowering IOP: netarsudil and the fixed-dose combination of netarsudil and latanoprost €15.00 Clinical safety and efficacy of the first-in-class Rho kinase inhibitor for lowering IOP: netarsudil and the fixed-dose combination of netarsudil and latanoprost quantity Add to cart Category: Articles Tag: Volume 3 Description Description Authors: Janet B. Serle, Jake Radell Related products Medical device basics €15.00 Add to cart The 810 Nm I.R. Diode Laser in the pivotal paradigm shift from laser photocoagulation to laser photostimulation €15.00 Add to cart Glaucoma and stem cells €15.00 Add to cart Autophagy in outflow pathway physiology and pathophysiology €15.00 Add to cart